Results 321 to 330 of about 177,994 (348)

???????????? ?????????????? ?? ?????????? BRCA1/2 ?? ???????????? ???? ????????????????/?????????????????? ?????? ???????????????? ????????????, ?????? ???????????????????? ?? ???????????????????? ?????????????? (??????????????)

2016
?????????????????? ???????????? ???????????????????????????? ?????????????? ?? ?????????? BRCA1/2 ?????????? ???? ?????????? ???????????????? ???????????? (??????) ?? ?????????? ?????????????? (????), ?????? ?????????? ?????????????????? ???????????????? ?????????????? ???????? ?????? ??????????????????. ???????????????????? ???????????????? 78 ????????
openaire   +1 more source

BRCA1 and its toolbox for the maintenance of genome integrity

Nature Reviews Molecular Cell Biology, 2009
Michael S Y Huen, Shirley M-H Sy, Junjie Chen   +2 more
exaly  

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study

Lancet, The, 2000
Steven A Narod, Mark E Robson, Ketil R Heimdal   +2 more
exaly  

Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation

Lancet, The, 2000
Maaike P G Vreeswijk
exaly  

Is there more to BARD1 than BRCA1?

Nature Reviews Cancer, 2006
Irmgard Irminger-Finger
exaly  

??????????????? ?????????????????????? ?? ???????????????????? ?????????????? ?? ???????????????????? ??53 ?? BRCA1, ???????????????????? ??????-?? ???? ??????-??

2011
????????????. ?????????????????? ???????????????????????? ???????????????????? ??????????????????????, ?????????????????? ??53 ?? BRCA1 ?? ?????????????? ?????????????? ??????????????, ?????????????????? ?? ?????????????????? ?????????????????? ?????? ???? ???????????? ??????-?? ???? ??????-??, ?? ?????????? ???????????? ?????? ?????????????????? ?? ???
openaire   +1 more source

Risks of cancer in BRCA1-mutation carriers

Lancet, The, 1994
D Timothy Bishop
exaly  

BRCA1 and BRCA2: 1994 and beyond

Nature Reviews Cancer, 2004
Steven A Narod, William D Foulkes
exaly  

Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1

Lancet, The, 1998
Maaike P G Vreeswijk
exaly  

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Lancet, The, 2010
Michael Friedlander, Clare L Scott, Jeffrey N Weitzel   +2 more
exaly